Cover Image
Market Research Report

Cervical Cancer - Epidemiology Forecast to 2030

Published by DelveInsight Business Research LLP Product code 963739
Published Content info 100 Pages
Delivery time: 1-2 business days
Price
Back to Top
Cervical Cancer - Epidemiology Forecast to 2030
Published: October 14, 2020 Content info: 100 Pages
Description

DelveInsight's 'Cervical Cancer - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical, and forecasted Cervical cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Cervical Cancer: Understanding

The DelveInsight's Cervical cancer epidemiology report gives a thorough understanding of cervical cancer by including details such as disease definition, staging, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Cervical cancer in the US, Europe, and Japan. Moreover, the report covers detailed information on the cervical cancer epidemiology scenario in seven major countries (US, EU5, and Japan).

Epidemiology Perspective by DelveInsight:

This section encompassing cervical cancer epidemiology provides insights about historical and current patient pool and forecasted trends for every seven major countries. The Cervical cancer epidemiology data are studied through all possible divisions to give a better understanding of the Disease scenario in 7MM. This segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports, and views of key opinion leaders.

Detailed Epidemiology Segmentation:

The Cervical cancer epidemiology covered in the report provides historical as well as forecasted Cervical cancer epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report:

  • The Cervical cancer report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Cervical cancer report and model provide an overview of the global trends of cervical cancer in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • The report provides insight into the historical and forecasted patient pool of Cervical cancer in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
  • The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
  • The report assesses the disease risk and burden and highlights the unmet needs of Cervical cancer.
  • The report provides the segmentation of the Cervical cancer epidemiology

Report Highlights::

  • 11-year Forecast of Cervical cancer Epidemiology
  • 7MM Coverage
  • Incident cases of Cervical Cancer
  • Stage-specific Incidence of Cervical Cancer
  • Histopathologic Types of Cervical Cancer
  • Age-specific cases of Cervical Cancer

KOL - Views:

We interview KOLs and include SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. It will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered:

  • What will be the growth opportunities in the 7MM concerning the patient population pertaining to Cervical Cancer?
  • What are the key findings pertaining to the Cervical cancer epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Cervical cancer across the 7MM during the forecast period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden, and unmet needs of Cervical Cancer?
  • What are the currently available treatments of Cervical Cancer?

Reasons to buy:

The Cervical cancer Epidemiology report will allow the user to:

  • Develop business strategies by understanding the trends shaping and driving the global Cervical cancer market.
  • Quantify patient populations in the global Cervical cancer market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Cervical cancer therapeutics in each of the markets covered
  • Understand the magnitude of Cervical cancer population by its epidemiology
  • The Cervical cancer Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments:

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population
Table of Contents

Table of Contents

1 Key Insights

2 Executive Summary of Cervical Cancer

3 SWOT Analysis for Cervical Cancer

4 Cervical Cancer Epidemiology Overview at a Glance

  • 4.1 Patient Share (%) Distribution of Cervical Cancer in 2017
  • 4.2 Patient Share (%) Distribution of Cervical Cancer in 2030

5 Cervical Cancer Market Overview at a Glance

  • 5.1 Market Share (%) Distribution of Cervical Cancer in 2017
  • 5.2 Market Share (%) Distribution of Cervical Cancer in 2030

6 Disease Background and Overview

  • 6.1 Introduction
  • 6.2 Definition
  • 6.3 Etiology
  • 6.4 Risk factors
  • 6.5 Staging
  • 6.6 Pathophysiology
  • 6.7 Diagnosis

Forty-year timeline of public health research and policy on HPV and cervical cancer

7 Epidemiology and Patient Population

  • 7.1 Key Findings
  • 7.2 Total Incident Population of Cervical Cancer in 7MM
  • 7.3 Assumption and Rationale: 7MM

8 Country Wise-Epidemiology of Cervical Cancer

  • 8.1 The United States
    • 8.1.1 Incident cases of Cervical Cancer in the United States
    • 8.1.2 Stage-specific Incidence of Cervical Cancer in the United States
    • 8.1.3 Histopathologic Types of Cervical Cancer in the United States
    • 8.1.4 Age-specific cases of Cervical Cancer in the United States
  • 8.2 Germany
    • 8.2.1 Incident cases of Cervical Cancer in Germany
    • 8.2.2 Stage-specific Incidence of Cervical Cancer in Germany
    • 8.2.3 Histopathologic Types of Cervical Cancer in Germany
    • 8.2.4 Age-specific cases of Cervical Cancer in Germany
  • 8.3 France
    • 8.3.1 Incident cases of Cervical Cancer in France
    • 8.3.2 Stage-specific Incidence of Cervical Cancer in France
    • 8.3.3 Histopathologic Types of Cervical Cancer in France
    • 8.3.4 Age-specific cases of Cervical Cancer in France
  • 8.4 Italy
    • 8.4.1 Incident cases of Cervical Cancer in Italy
    • 8.4.2 Stage-specific Incidence of Cervical Cancer in Italy
    • 8.4.3 Histopathologic Types of Cervical Cancer in Italy
    • 8.4.4 Age-specific cases of Cervical Cancer in Italy
  • 8.5 Spain
    • 8.5.1 Incident cases of Cervical Cancer in Spain
    • 8.5.2 Stage-specific Incidence of Cervical Cancer in Spain
    • 8.5.3 Histopathologic Types of Cervical Cancer in Spain
    • 8.5.4 Age-specific cases of Cervical Cancer in Spain
  • 8.6 The United Kingdom
    • 8.6.1 Incident cases of Cervical Cancer in the United Kingdom
    • 8.6.2 Stage-specific Incidence of Cervical Cancer in the United Kingdom
    • 8.6.3 Histopathologic Types of Cervical Cancer in the United Kingdom
    • 8.6.4 Age-specific cases of Cervical Cancer in the United Kingdom
  • 8.7 Japan
    • 8.7.1 Incident cases of Cervical Cancer in Japan
    • 8.7.2 Stage-specific Incidence of Cervical Cancer in Japan
    • 8.7.3 Histopathologic Types of Cervical Cancer in Japan
    • 8.7.4 Age-specific cases of Cervical Cancer in Japan

9 Treatment and Management

  • 9.1 Side effects of treatment
  • 9.2 Prevention of Cervical cancer
  • 9.3 Guidelines
    • 9.3.1 NCCN Guidelines
    • 9.3.2 ESMO guidelines
    • 9.3.3 Japan Society of Gynecologic Oncology (JSGO) Guidelines
  • 9.4 Patient Journey

10 Unmet Needs

11 Appendix

  • 11.1 Report Methodology

12 DelveInsight Capabilities

13 Disclaimer

14 About DelveInsight

List of Tables

  • Table 1: Summary of Cervical Cancer Market, Epidemiology, and Key Events (2017-2030)
  • Table 2: Total cases of Cervical Cancer in 7MM (2017-2030)
  • Table 3: Incident cases of Cervical Cancer in the United States (2017-2030)
  • Table 4: Stage-specific Incidence of Cervical Cancer in the United States(2017-2030)
  • Table 5: Histopathologic Types of Cervical Cancer in the United States(2017-2030)
  • Table 6: Age-specific cases of Cervical Cancer in the United States(2017-2030)
  • Table 7: Incident cases of Cervical Cancer in Germany (2017-2030)
  • Table 8: Stage-specific Incidence of Cervical Cancer in Germany(2017-2030)
  • Table 9: Histopathologic Types of Cervical Cancer in Germany(2017-2030)
  • Table 10: Age-specific cases of Cervical Cancer in Germany(2017-2030)
  • Table 11: Incident cases of Cervical Cancer in France (2017-2030)
  • Table 12: Stage-specific Incidence of Cervical Cancer in France(2017-2030)
  • Table 13: Histopathologic Types of Cervical Cancer in France(2017-2030)
  • Table 14: Age-specific cases of Cervical Cancer in France(2017-2030)
  • Table 15: Incident cases of Cervical Cancer in Italy (2017-2030)
  • Table 16: Stage-specific Incidence of Cervical Cancer in Italy(2017-2030)
  • Table 17: Histopathologic Types of Cervical Cancer in Italy(2017-2030)
  • Table 18: Age-specific cases of Cervical Cancer in Italy(2017-2030)
  • Table 19: Incident cases of Cervical Cancer in Spain (2017-2030)
  • Table 20: Stage-specific Incidence of Cervical Cancer in Spain(2017-2030)
  • Table 21: Histopathologic Types of Cervical Cancer in Spain(2017-2030)
  • Table 22: Age-specific cases of Cervical Cancer in Spain(2017-2030)
  • Table 23: Incident cases of Cervical Cancer in the United Kingdom (2017-2030)
  • Table 24: Stage-specific Incidence of Cervical Cancer in the United Kingdom(2017-2030)
  • Table 25: Histopathologic Types of Cervical Cancer in the United Kingdom(2017-2030)
  • Table 26: Age-specific cases of Cervical Cancer in the United Kingdom(2017-2030)
  • Table 27: Incident cases of Cervical Cancer in Japan (2017-2030)
  • Table 28: Stage-specific Incidence of Cervical Cancer in Japan(2017-2030)
  • Table 29: Histopathologic Types of Cervical Cancer in Japan(2017-2030)
  • Table 30: Age-specific cases of Cervical Cancer in Japan(2017-2030)

List of Figures

  • Figure 1: SWOT Analysis
  • Figure 2: Terminology of cervical disease categories
  • Figure 3: Risk factors for cervical cancer
  • Figure 4: Risk factors for cervical cancer
  • Figure 5: Risk factors for cervical cancer
  • Figure 6: Timeline of public health research and policy of HPV and cervical cancer
  • Figure 7: Total Incident cases of Cervical Cancer in 7MM (2017-2030)
  • Figure 8: Incident cases of Cervical Cancer in the United States (2017-2030)
  • Figure 9: Stage-specific Incidence of Cervical Cancer in the United States (2017-2030)
  • Figure 10: Histopathologic Types of Cervical Cancer in the United States (2017-2030)
  • Figure 11: Age-specific cases of Cervical Cancer in the United States (2017-2030)
  • Figure 12: Incident cases of Cervical Cancer in Germany (2017-2030)
  • Figure 13: Stage-specific Incidence of Cervical Cancer in Germany (2017-2030)
  • Figure 14: Histopathologic Types of Cervical Cancer in Germany (2017-2030)
  • Figure 15: Age-specific cases of Cervical Cancer in Germany (2017-2030)
  • Figure 16: Incident cases of Cervical Cancer in France (2017-2030)
  • Figure 17: Stage-specific Incidence of Cervical Cancer in France (2017-2030)
  • Figure 18: Histopathologic Types of Cervical Cancer in France (2017-2030)
  • Figure 19: Age-specific cases of Cervical Cancer in France (2017-2030)
  • Figure 20: Incident cases of Cervical Cancer in Italy (2017-2030)
  • Figure 21: Stage-specific Incidence of Cervical Cancer in Italy (2017-2030)
  • Figure 22: Histopathologic Types of Cervical Cancer in Italy (2017-2030)
  • Figure 23: Age-specific cases of Cervical Cancer in Italy (2017-2030)
  • Figure 24: Incident cases of Cervical Cancer in Spain (2017-2030)
  • Figure 25: Stage-specific Incidence of Cervical Cancer in Spain (2017-2030)
  • Figure 26: Histopathologic Types of Cervical Cancer in Spain (2017-2030)
  • Figure 27: Age-specific cases of Cervical Cancer in Spain (2017-2030)
  • Figure 28: Incident cases of Cervical Cancer in the United Kingdom (2017-2030)
  • Figure 29: Stage-specific Incidence of Cervical Cancer in the United Kingdom (2017-2030)
  • Figure 30: Histopathologic Types of Cervical Cancer in the United Kingdom (2017-2030)
  • Figure 31: Age-specific cases of Cervical Cancer in the United Kingdom (2017-2030)
  • Figure 32: Incident cases of Cervical Cancer in Japan (2017-2030)
  • Figure 33: Stage-specific Incidence of Cervical Cancer in Japan (2017-2030)
  • Figure 34: Histopathologic Types of Cervical Cancer in Japan (2017-2030)
  • Figure 35: Age-specific cases of Cervical Cancer in Japan (2017-2030)
  • Figure 36: Surgical treatment options for cervical cancer
  • Figure 37: Radiation treatment options for cervical cancer
  • Figure 38: Chemotherapy treatment options for cervical cancer
  • Figure 39: Workup for cervical cancer
  • Figure 40: Primary treatment for cervical cancer
  • Figure 41: Primary treatment for cervical cancer
  • Figure 42: Primary treatment for cervical cancer
  • Figure 43: Adjuvant treatment of cervical cancer
  • Figure 44: Patient Journey of Cervical Cancer
  • Figure 45: Unmet needs for cervical cancer
  • Figure 46: Market drivers for Cervical cancer
  • Figure 47: Market Barriers for Cervical cancer
Back to Top